Remove 2004 Remove Competition Remove Healthcare
article thumbnail

Botanical drugs – what is the best way forward for regulatory and market approval?

European Pharmaceutical Review

2 Approach taken by regulators in the UK The Medicines and Healthcare products Regulatory Agency regulates herbal medicines in the UK. 10 Directive 2004/24/EC introduced a registration scheme for traditional herbal medicines and requires herbal remedies sold over the counter in the UK to be registered. 2012/1916). Ethnopharmacol.

Marketing 103
article thumbnail

Pharma responds to proposed EU pharmaceutical legislation reform

European Pharmaceutical Review

Pinsent Masons Charlotte Weekes, Senior Associate at Pinsent Masons shared with EPR : “The Commission’s ambitious pharma legislation review is the first significant review of the European system since 2004.” “It "Our concern is that the pharma legislation is not there yet."

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

New Bill could enhance UK clinical trial regulation

European Pharmaceutical Review

If achieved, this would boost the UK’s competitiveness as a leading international site for trials. This activity should bring together relevant data sets which are collected by both the Medicines and Healthcare products Regulatory Agency (MHRA) and HRA. Mansfield also listed the main elements of The Future Clinical Trials Bill.

Ethics 105
article thumbnail

A glance back to Pharma Integrates, London 2022 – part ii

pharmaphorum

Modern healthcare: the NHS is a failing system Berry began by reflecting on Lord Prior’s curriculum vitae: barrister, trained in finance, MP, chair of Norwich hospital trust, health minister, life sciences minister, chair of NHS England – she quipped that he was ‘definitely qualified’ for the event. Highly unlikely.”

Pharma 75
article thumbnail

Sweeping changes in leaked EU pharma law draft reignite profit vs access conflict

Pharmaceutical Technology

The revision process is reviving old conflicts in the pharma industry over fair and affordable access to medicines versus Europe’s status as a competitive home for pharma innovation. EU competitiveness Moll said the legislation revisions should instead be used to make Europe more attractive to pharma companies.

Pharma 64
article thumbnail

Interchangeability of biosimilars in the EU – the industry impact

European Pharmaceutical Review

She has experience on issues arising during the lifecycle of medicinal products, including optimisation of IP regulatory rights, advertising, product liability, competition and market access issues. Chris was named a ‘Rising Star’ in the 2022 Legal 500 Rankings for Life Sciences and Healthcare. References/Endnotes. Lausuntopalvelu.fi.

article thumbnail

The EU HTA regulation: a new frontier for access to innovative technologies

European Pharmaceutical Review

border healthcare, specifically by repealing Article 15, which originally laid down the modalities and principles for co-operation between Member States in assessing new health technologies. governmental healthcare organisations. Vincenzo Salvatore is of counsel and leader of the Healthcare and Life Sciences Focus Team at BonelliErede.